Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that the recent launch of the first generic paroxetine product in the United States, together with the prospective launch of generic citalopram, will have a more profound effect on prescribing behavior in the U.S. antidepressant market than did the launch in 2001 of generic fluoxetine. The new PhysicianForum report entitled Potential Impact of Generic Citalopram and Paroxetine on the Antidepressant Market finds that the availability of generic paroxetine and citalopram will prompt many physicians to switch patients not only from their respective originator products, Paxil and Celexa, but also from other antidepressants (e.g., Zoloft, Effexor XR, Lexapro).
"Physicians' likelihood of prescribing generic citalopram or paroxetine is inversely proportional to the cost of therapy," said Neil Grubert, analyst at Decision Resources. "At a daily cost of 25 cents or less, 79% of primary care physicians (PCPs) and more than 50% of psychiatrists would definitely prescribe these generics. However, if these products arrive to market at a daily cost of more than $2.49, 75% or more of PCPs and 57% or more of psychiatrists would definitely not prescribe them."
The primary research report also finds that generic citalopram and paroxetine would have a greater effect on the prescribing behavior of PCPs than on that of psychiatrists. Sixty-four percent of PCPs and 53% of psychiatrists would be more inclined to prescribe citalopram if it were available as a generic. Similarly, 61% of PCPs and 50% of psychiatrists would be more likely to prescribe paroxetine if it were available as a generic.
Potential Impact of Generic Citalopram and Paroxetine on the Antidepressant Market is based on a survey of 24 HMO pharmacy directors, 56 PCPs, and 30 psychiatrists throughout the United States. Their responses were compared to assess similarities and differences in clinical, economic, and scientific factors.
PhysicianForum is a new primary research service from Decision Resources. The service offers access to high volume-prescribing PCPs, specialists, and managed care organization representatives in the United States, analysis of events and survey participants' responses to them, insight into prescribing patterns, and an examination of the implications for the pharmaceutical market.
About Decision Resources
Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/